LAS VEGAS (MedPage Today) -- The oral BRAF inhibitor vemurafenib (Zelboraf) increased survival in patients with metastatic melanoma, but the cost may not justify its use in a state Medicaid program, an analysis suggested. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment